Mineralys Therapeutics (MLYS) CMO reports major option exercises and sales
Rhea-AI Filing Summary
Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reportedmultiple stock option exercises and related share sales in early January 2026. On January 2, 2026, he exercised options for 10,053, 3,629, 9,347, 20,168 and 24,193 shares of common stock at exercise prices of $1.08, $15.44, $10.20, $16.00 and $14.25, respectively, then sold 70,037 shares at a weighted-average price of $35.8656.
On January 5, 2026, he exercised additional options for 28,038, 10,121, 26,069, 53,630 and 67,473 shares at the same exercise prices, and sold 139,245 shares at a weighted-average price of $34.8275 and 53,470 shares at a weighted-average price of $35.5256. Following the last reported transaction, he directly owned 61,804 common shares, which includes 680 shares purchased under the 2023 Employee Stock Purchase Plan that were not previously reported. All transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 28,038 | $0.00 | -- |
| Exercise | Stock Option | 10,121 | $0.00 | -- |
| Exercise | Stock Option | 26,069 | $0.00 | -- |
| Exercise | Stock Option | 53,630 | $0.00 | -- |
| Exercise | Stock Option | 67,473 | $0.00 | -- |
| Exercise | Common Stock | 28,038 | $1.08 | $30K |
| Exercise | Common Stock | 10,121 | $15.44 | $156K |
| Exercise | Common Stock | 26,069 | $10.20 | $266K |
| Exercise | Common Stock | 53,630 | $16.00 | $858K |
| Exercise | Common Stock | 67,473 | $14.25 | $961K |
| Sale | Common Stock | 139,245 | $34.8275 | $4.85M |
| Sale | Common Stock | 53,470 | $35.5256 | $1.90M |
| Exercise | Stock Option | 10,053 | $0.00 | -- |
| Exercise | Stock Option | 3,629 | $0.00 | -- |
| Exercise | Stock Option | 9,347 | $0.00 | -- |
| Exercise | Stock Option | 20,168 | $0.00 | -- |
| Exercise | Stock Option | 24,193 | $0.00 | -- |
| Exercise | Common Stock | 10,053 | $1.08 | $11K |
| Exercise | Common Stock | 3,629 | $15.44 | $56K |
| Exercise | Common Stock | 9,347 | $10.20 | $95K |
| Exercise | Common Stock | 20,168 | $16.00 | $323K |
| Exercise | Common Stock | 24,193 | $14.25 | $345K |
| Sale | Common Stock | 70,037 | $35.8656 | $2.51M |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. This balance includes 680 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.6550 to $36.4522. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.2100 to $35.2021. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.2100 to $35.7700. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
FAQ
Who is the insider in the Mineralys Therapeutics (MLYS) Form 4 filing?
The Form 4 reports transactions by Rodman David Malcom, who serves as Chief Medical Officer of Mineralys Therapeutics, Inc. and is an officer but not a director or 10% owner.
What stock option exercises did the Mineralys Therapeutics CMO report?
On January 2, 2026, he exercised options for 10,053, 3,629, 9,347, 20,168 and 24,193 shares at exercise prices of $1.08, $15.44, $10.20, $16.00 and $14.25. On January 5, 2026, he exercised additional options for 28,038, 10,121, 26,069, 53,630 and 67,473 shares at the same respective exercise prices.
Were the Mineralys Therapeutics insider transactions under a Rule 10b5-1 plan?
Yes. A footnote states that all the reported transactions were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 6, 2025.
What do the footnotes say about the reported sale prices in the Mineralys Form 4?
For each sale, the reported price is described as a weighted-average price, with shares sold in multiple transactions within specified price ranges. The reporting person undertakes to provide full information on the number of shares sold at each separate price within those ranges upon request.